We are today happy to announce that Hubro Bioscience and Fürst Medisinske Laboratorium have signed a collaboration agreement for the next phase of the development of Hubro’s diagnostic tools for the specific detection of MSI-cancer related biomarkers in liquid biopsies.
Fürst, with their extensive experience and competence within the field of diagnostics, will secure professional advancement of Hubro’s technology towards commercial manufacturing, clinical validation and commercialization.
The collaboration entails optimization of test-assays, design of prototype kits and conducting a pilot study for initial clinical validation.